cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Recursion Pharmaceuticals A
5 own
3 watching
Current Price
$0
$0.13
(1.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,756.99M
52-Week High
52-Week High
14.18
52-Week Low
52-Week Low
4.54
Average Volume
Average Volume
0.25M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,756.99M
icon52-Week High14.18
icon52-Week Low4.54
iconAverage Volume0.25M
iconDividend Yield--
iconP/E Ratio--
What does the Recursion Pharmaceuticals A do?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Recursion Pharmaceuticals A make?
News & Events about Recursion Pharmaceuticals A.
Zolmax
2 months ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) CEO Christopher Gibson sold 70,890 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $8.10, for a total transaction of $574,209.00. Following the sale, ...
Globe Newswire
3 months ago
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media & Telecom ...
Globe Newswire
3 months ago
Salt Lake City, Utah, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. On Rare Disease Day, Feb. 28, 2023, community ...
PR Newswire
5 months ago
Recursion to Participate in Upcoming Investor Conferences Recursion to Participate in Upcoming Investor Conferences PR Newswire SALT LAKE CITY, Dec. 20, 2022 SALT LAKE CITY, Dec. 20, 2022 /PRNewswire/ --Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug...
Zolmax
8 months ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) insider Shafique Virani sold 10,000 shares of the businesss stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $13.36, for a total value of $133,600.00. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Recursion Pharmaceuticals A share price today?
plus_minus_icon
Can Indians buy Recursion Pharmaceuticals A shares?
plus_minus_icon
How can I buy Recursion Pharmaceuticals A shares from India?
plus_minus_icon
Can Fractional shares of Recursion Pharmaceuticals A be purchased?
plus_minus_icon
What are the documents required to start investing in Recursion Pharmaceuticals A stocks?
plus_minus_icon
What is today’s traded volume of Recursion Pharmaceuticals A?
plus_minus_icon
What is today’s market capitalisation of Recursion Pharmaceuticals A?
plus_minus_icon
What is the 52-Week High and Low Range of Recursion Pharmaceuticals A?
plus_minus_icon
What percentage is Recursion Pharmaceuticals A down from its 52-Week High?
plus_minus_icon
What percentage is Recursion Pharmaceuticals A up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.13
(1.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00